Some features may not work as expected in this browser. For the full NewsNow experience, please consider updating your browser or trying a different device. Some features may not work as expected.
Please consider updating your browser or device.

You’re on our free ad-supported tier. Upgrade to NewsNow Essentials for just £4/m now! Your favourite news platform, faster, slicker and ad free.You’re on our free tier. Get NewsNow Essentials at just £4/m now!. Faster, slicker and ad free.You’re on our free tier. Go ad free for just £4/m now!

Home
Hot Topics
US
Politics
World
Sports
Business
Crypto
Entertainment
Lifestyle
AI
Tech
Science

Novartis
Pharmaceuticals
AstraZeneca
Sanofi
GSK
Johnson & Johnson
Novo Nordisk
Topics

Advertisement

Advertisement

Novartis

Share

Top Latest Popular

What Monte Rosa Therapeutics (glue)'s Phase 2 trial start means for shareholders Simply Wall St 1d

Simply Wall St 1d

Narasimhan Stands By Novartis M&A Record Despite Setbacks Scrip Pharma Intelligence 16:50 Fri, 11 Sep

Scrip Pharma Intelligence 16:50 Fri, 11 Sep

Amgen confident in cardiometabolic pipeline after Novartis’s negative lp(a) readout Scrip Pharma Intelligence 7d

Scrip Pharma Intelligence 7d

Advertisement

Novartis’s VHB937 latest to join als clinical development graveyard Scrip Pharma Intelligence 7d

Scrip Pharma Intelligence 7d

Advertisement

Should multiple sclerosis trial win require action from Novartis (swx:Novn) investors? Simply Wall St 21:23 Tue, 15 Sep

Simply Wall St 21:23 Tue, 15 Sep

Pressure intensifies on Novartis as bolt-on deal strategy faces major test Clinical Trials Arena 11:42 Mon, 14 Sep

Clinical Trials Arena 11:42 Mon, 14 Sep

Advertisement

Advertisement

Latest

Yesterday

Myotonic Dystrophy Market Expected to Grow Rapidly During the Forecast Period (2026-2036) as Pipeline Therapies Address Unmet Medical Needs | DelveInsight PR Newswire (Press Release) 15:34 Wed, 23 Sep

BoomRay and Novartis Pharma sign $900m deal for radioligand therapy Pharmaceutical Business Review 10:45 Wed, 23 Sep

Tuesday

What Monte Rosa Therapeutics (GLUE)'s Phase 2 Trial Start Means For Shareholders Simply Wall St 18:57 Tue, 22 Sep

Novartis locks in preclinical Rlt under $900M Boomray deal BioWorld 18:34 Tue, 22 Sep

Europe Is Losing the Pharma Investment Race – But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi Novartis (Press Release) 14:02 Tue, 22 Sep

Fortune includes Novartis in 2026 Change The World List for malaria program Novartis (Press Release) 14:02 Tue, 22 Sep

BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset PR Newswire (Press Release) 05:04 Tue, 22 Sep

Novartis (SWX:NOVN) Has Fresh Attention, What Are Investors Weighing Now? Simply Wall St 02:59 Tue, 22 Sep

American Chemical Society honors Novartis researchers Novartis (Press Release) 01:19 Tue, 22 Sep

Monday

Novartis’s Christian Diehl on scaling AI beyond the demo The McKinsey Quarterly 17:11 Mon, 21 Sep

Advertisement

Advertisement

Advertisement

Advertisement

About our Novartis news

Latest news for Novartis, a global healthcare company based in Switzerland specialising in pharmaceuticals, including updates on company and product news.

News Now

Our Sites

News Now Nigeria

News Now România

News Now Italia

News Now Canada

News Now Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Back to Business Pharmaceuticals
- Abbott Laboratories
- AbbVie AbbVie
- AstraZeneca
- Baxter Baxter
- Bayer Bayer
- Boehringer Ingelheim
- Bristol Myers Squibb
- Eli Lilly Eli Lilly
- Genentech Genentech
- GlaxoSmithKline
- Johnson and Johnson
- Merck and Co
- Novartis Novartis
- Novavax Novavax
- Novo Nordisk
- Pfizer Pfizer
- Roche Roche
- Sanofi Sanofi
- Takeda Takeda
- Teva Teva
- Zoetis Zoetis